# Ansa Biotechnologies, Inc.

> Ansa Biotechnologies is an Emeryville, California biotech company that makes custom synthetic DNA using a proprietary enzymatic synthesis platform. Its no-assembly approach can build long, complex, high-fidelity DNA sequences - including clonal constructs up to 50 kilobases - that stump legacy chemical methods, and it backs delivery with an industry-first On-Time Guarantee. Founded in 2018 by UC Berkeley researchers, Ansa serves scientists across pharmaceuticals, gene therapy, agriculture, and industrial biotech.

- **Founded:** 2018
- **Headquarters:** Emeryville, California, United States
- **Founders:** Dan Lin-Arlow (Co-founder & Chief Scientific Officer), Sebastian Palluk (Co-founder & Chief Technology Officer), Jared Ellefson (Co-founder)
- **Team size:** ~76 employees
- **Products:** Clonal DNA (Standard & XL), DNA Fragments, Catalog Vectors, Custom Vector Synthesis, On-Time Guarantee
- **Notable:** Launched the world's longest commercially available sequence-perfect synthetic DNA at 50 kb (October 2025)., Developed a proprietary enzymatic (TdT-dNTP conjugate) DNA synthesis platform requiring no assembly., Introduced the industry's first On-Time Guarantee for custom DNA delivery.

## Products & services

- **Clonal DNA (Standard & XL)** — Sequence-perfect, clonally verified double-stranded DNA, including XL formats up to 50 kilobases - the longest commercially available sequence-perfect synthetic DNA.
- **DNA Fragments** — Direct enzymatic synthesis of linear double-stranded DNA fragments up to ~900 bp with no assembly required.
- **Catalog Vectors** — Ready-to-order cloning, bacterial, mammalian, AAV, and transcription vector backbones.
- **Custom Vector Synthesis** — Bespoke vector design and synthesis, offered through an early access program.
- **On-Time Guarantee** — Industry-first commitment: your complete order delivered on time, or it's free.

## Achievements

- Launched the world's longest commercially available sequence-perfect synthetic DNA at 50 kb (October 2025).
- Developed a proprietary enzymatic (TdT-dNTP conjugate) DNA synthesis platform requiring no assembly.
- Introduced the industry's first On-Time Guarantee for custom DNA delivery.
- Raised more than $130M in total funding across Series A and Series B rounds.
- Grew from 2 co-founders to 70+ employees since 2018.
- Founders named as co-inventors on 9-11 patent families related to enzymatic DNA synthesis.

## Latest updates

- **2025-10** — Launched 50 kb Clonal DNA - the longest sequence-perfect synthetic DNA commercially available, deliverable in 25 days or less.
- **2025-10** — Closed an oversubscribed $54.4M Series B led by Cerberus Ventures to scale US-based DNA manufacturing.
- **2022-04** — Closed an oversubscribed $68M Series A led by Northpond Ventures.

## Links

- Website: https://ansabio.com
- LinkedIn: http://www.linkedin.com/company/ansabio
- Twitter/X: https://twitter.com/AnsaBio

---

Profile page: https://yespress.io/ansa-biotechnologies-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-13